Article citationsMore>>

T. Ishikawa, K. Higuchi, T. Kubota, et al., “Combination PEG-IFN-2b/Ribavirin Therapy Following Treatment of Hepatitis C Virus-Associated Hepatocellular Carcinoma Is Capable of Improving Hepatic Functional Reserve and Survival,” Hepatogastroenterology, Vol. 59, No. 114, 2012, pp. 529-532. doi:10.5754/hge10867

has been cited by the following article:

• TITLE: Treatment Strategy for Recurrent Multiple Hepatocellular Carcinoma

  AUTHORS: Toru Ishikawa

  KEYWORDS: Hepatocellular Carcinoma; Multiple Recurrence; Strategy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.2A, February 28, 2013

  ABSTRACT: Hepatocellular carcinoma (HCC) has some unique characteristics in the digestive organ cancer. Therefore it is very important to select an appropriate treatment for recurrent HCC according to several situations such as the type of recurrence, previous treatments and conditions of patient. This article is a review of the concept of recurrent multiple HCC and its therapeutic strategies.